Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-18, Stock:ABBV, The news for the past five days is as follows:
2018-06-11: NEWS1: JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space.NEWS2: JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space.NEWS3: Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval.NEWS4: Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval.NEWS5: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.NEWS6: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.NEWS7: Abbvie/Roche&apos;s Leukemia Drugs Combination Gets FDA Approval.NEWS8: JAK Inhibitors&apos; Prospects Strong: 4 Stocks Ruling the Space.NEWS9: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.
2018-06-12: NEWS1: AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018).
2018-06-13: NEWS1: ABBV Makes Notable Cross Below Critical Moving Average.NEWS2: ABBV Makes Notable Cross Below Critical Moving Average.NEWS3: Notable ETF Inflow Detected - XLV, ABBV, AMGN, MDT.NEWS4: Notable ETF Inflow Detected - XLV, ABBV, AMGN, MDT.NEWS5: Humira's Sales Will Decline -- and It's Fantastic News for AbbVie.NEWS6: Humira's Sales Will Decline -- and It's Fantastic News for AbbVie.NEWS7: Humira&apos;s Sales Will Decline -- and It&apos;s Fantastic News for AbbVie.
2018-06-14: NEWS1: AbbVie Declares Quarterly Dividend.
2018-06-15: NEWS1: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR.NEWS2: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR.NEWS3: MARKETS: Here's why stocks are dropping right now.NEWS4: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS5: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS6: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS7: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS8: Pharma Stock Roundup: LLY/AZN Alzheimer&apos;s Drug Fails, MRK&apos;s Keytruda Wins Approvals.NEWS9: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS10: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS11: Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro — Research Highlights Growth, Revenue, and Consolidated Results.NEWS12: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress.

Answer: Decrease